Deep vein thrombosis with pulmonary thromboembolism in a case of severe COVID-19 pneumonia

Sujata Devi,1 Sudipta Mohakud,2 Nilanjan Kar,1 Divya Muthuvel2

SUMMARY
A 53-year-old man with diabetes came to the emergency department with fever and dry cough for 5 days, swelling of the left leg for 2 days, shortness of breath and chest pain for 1 hour. He had raised temperature, tachycardia, tachypnoea, reduced oxygen saturation and swollen tender left leg on examination. The frontal chest radiograph showed bilateral ground-glass opacities; he tested positive for COVID-19 with elevated D-dimer. The colour Doppler examination of the left leg revealed acute deep vein thrombosis (DVT) of the common femoral and the popliteal veins. The chest CT showed bilateral diffuse ground-glass opacities predominantly involving peripheral zones and the lower lobes. The CTPA revealed left pulmonary thromboembolism (PTE), treated with low-molecular-weight heparin. COVID-19 predominantly affects the respiratory system. DVT and PTE are common in COVID-19 but lethal. They should be diagnosed early by clinical and radiological examinations and treated promptly with anticoagulants.

BACKGROUND
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was declared a pandemic by the WHO on March 11, 2020.1 2 Although it primarily affects the respiratory system, there are abundant reports on thrombotic complications. In patients with COVID-19, diagnosis of deep vein thrombosis (DVT) and pulmonary embolism may be challenging because of overlapping of symptoms.3 We report a case of COVID-19 associated with pulmonary embolism and DVT in a 53-year-old man.

CASE PRESENTATION
A 53-year-old man who was a known case of type 2 diabetes mellitus, presented to the emergency department with a history of fever and dry cough for 5 days, swelling of the left leg for 2 days, and shortness of breath and chest pain for 1 hour. On examination, his pulse rate was 138 beats/min, with blood pressure of 138/70 mm Hg, respiratory rate of 30 breaths/min, and oxygen saturation was 64% on room air with a temperature of 98.6°F. His left leg was swollen, and tenderness was present over the calf region (figure 1). A difference of 5 cm was observed between the left and right calf diameters. On auscultation, bilateral basal crepitation was found. The abdominal, neurological and cardiovascular systems were within normal limits.

INVESTIGATIONS
Laboratory tests showed haemoglobin of 1.41 g/L, total leucocyte count of 10×109 cells/L (with neutrophils of 81% and lymphocyte of 13%), total platelet count of 234×109 cells/L, random blood sugar level of 481 mg/dL, elevated D-dimer of 35.2 µg/L, lactate dehydrogenase of 724 U/L, with normal liver and kidney functions test. The nasal swab for COVID-19 real-time PCR test was positive. A Chest X-ray revealed GGOs on bilateral lung fields attributed to COVID-19 disease (figure 2).

Colour Doppler study of the left lower limb showed distended, non-compressible common femoral, superficial femoral and popliteal veins, which did not show colour filling or spectral waveform. No flow was seen even in the augmentation test by distal compression. These grey-scale and colour Doppler features were suggestive of acute deep venous thrombosis. CT pulmonary angiography (CTPA) was done to rule out pulmonary thromboembolism (PTE) as the patient has DVT with sudden-onset breathlessness, raised D-dimer and positive PCR test for COVID-19, which itself is now thought to incite inflammation and thrombosis. The CTPA showed a non-enhancing hypodense filling defect in the left main pulmonary artery extending into left lingular and superior basal segmental arteries suggestive of acute PTE (figure 3A,B). The CT sections of the lower limb in the venous phase also revealed the DVT as a hypodense filling defect in the expanded common femoral, superficial femoral and popliteal veins (figure 4A,B). Diffuse GGO and interlobular septal thickening were noted, predominantly involving peripheral zones of bilateral lungs, more so in the
lower lobes consistent with COVID-19 Reporting and Data System (CORADS) 6 (figure 5). The scoring on CT was 12/25, almost affecting 48% of the lung parenchyma.

**TREATMENT**

The patient was started on high flow oxygen at 12 L/min through a face mask. Oxygen saturation was maintained at 95%, and the respiratory rate decreased to 22 breaths/min. The patient started on injection of low-molecular-weight heparin 60 mg subcutaneous two times per day for DVT with pulmonary embolism. The patient started on injection of methylprednisolone 50 mg intravenous daily, injection of remdesivir 200 mg intravenous on the first day followed by 100 mg intravenous infusion for the next 4 days, injection of doxycycline 100 mg two times per day, ivermectin tablet 18 mg daily on an empty stomach for 3 days, along with zinc and vitamin C. Gradually, oxygen requirement decreased, and swelling of the leg decreased. The patient was discharged in good condition after 2 weeks of admission to this hospital with warfarin 5 mg/day.

**OUTCOME AND FOLLOW-UP**

The limb pain had subsided with reduced swelling at follow-up after 1 month. The patient complained of mild swelling on prolonged standing and was advised to use compression stockings and limb elevation. Follow-up colour Doppler imaging showed recanalisation of the thrombosed vessels with wall thickening.

**DISCUSSION**

Coronaviruses are a group of enveloped RNA viruses responsible for upper respiratory tract diseases, out of which SARS-CoV-2 is known to cause severe and fatal disease in humans. Patients affected by COVID-19 mostly present with fever, dry cough, malaise and shortness of breath. Patients with COVID-19 have a very high risk of developing DVT. The common symptoms and signs of DVT are swelling, redness and tenderness of the lower limbs. In our patient, all the typical symptoms and signs of COVID-19 and DVT are present.

DVT and PTE in patients with COVID-19 occur mainly due to increased inflammatory response due to the release of proinflammatory cytokines combined with hypoxia, immobilisation and disseminated vascular coagulation. Hypoxia acts as a prothrombotic condition by increasing blood viscosity and
triggering a transcription factor-mediated thrombotic pathway. This can also be due to the disruption of vascular endothelium caused by the viral infection itself. The other risk factors for DVT development are severely ill patients in the intensive care unit, mechanical ventilation, infection, cancer, obesity, comorbidities, male sex and old age. Elevation of D-dimer levels and fibrin degradation products seen in patients with COVID-19 are due to the breakdown of fibrin clots. In the case of COVID-19 pneumonia, which is a prothrombotic condition, the presence of a swollen, painful limb should raise the suspicion of DVT. A progressive increase in breathlessness with falling oxygen saturation, especially with associated DVT and raised D-dimer level, should raise the suspicion of PTE. Duplex ultrasound of the venous system of the affected limb confirms the diagnosis of DVT. CTPA can clearly demonstrate the pulmonary arterial thrombus even in the subsegmental arteries.

The use of prophylactic anticoagulation in hospitalised patients with COVID-19 decreases venous thromboembolism (VTE) and also decreases mortality. A retrospective study by Lodigiani et al. reported a 21% incidence of VTE within 24 hours of admission, whereas Klok et al. reported a 31% VTE even after thromboprophylaxis. A study by Middeldorp et al. reported that incidence of VTE among hospitalised patients with COVID-19 undergoing thromboprophylaxis was 16%, 33% and 42% at days 7, 14 and 21, respectively. However, ambulation should be the mainstay of thromboprophylaxis in patients who do not require admission. Unfractionated heparin and low-molecular-weight heparin can be used both prophylactically and therapeutically. Patients with COVID-19 with documented VTE require a minimum of 3 months of anticoagulation.

SARS-CoV-2 is known to cause a more severe form of pneumonia in human beings causing severe morbidity and mortality. COVID-19 association with DVT and pulmonary embolism is common yet very critical and lethal and should be detected early by proper clinical examination, using colour Doppler venous ultrasound and CT pulmonary angiogram. The use of anticoagulants judiciously will prevent further complications.

**Contributors**

SD: primary consultant of the patient, clinical history, follow-up, drafting of the manuscript and manuscript review; SM: radiological diagnosis, drafting of the manuscript and manuscript review; NK: clinical data collection and drafting of the manuscript; DM: collection of radiological data and manuscript editing.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

None declared.

**Patient consent for publication**

Obtained.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

**REFERENCES**

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
2. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 -11 March 2020, 2020. Available: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020
3. Middeldorp S, Couppes M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020;18:1995–2002.
4. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020;191:9–14.
5. Klok FA, Kruij MHA, van der Meer NM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.
6. Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 2020;39:5.
7. Atalaih B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother 2020;6:260–1.
8. Khan IH, Savarimuthu S, Leung MST, et al. The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg 2020;72:799–804.
9. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-COV-1, MERS-Cov and lessons from the past. J Clin Virol 2020;127:104362.
10. Mondal S, Quintili AL, Karamchandani K, et al. Thromboembolic disease in COVID-19 patients: a brief narrative review. J Intensive Care 2020;8:70.
11. Thachil J, Tang N, Gando S, et al. Type and dose of heparin in Covid-19: reply. J Thromb Haemost 2020;18:2063–4.
12. Bein-Apak FB, Sarialioglu F. The old but new: can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? Med Hypotheses 2020;142:109743.
13. Moores LK, Triteschler T, Brosnanah S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: chest guideline and expert panel report. Chest 2020;158:1143–63.
